期刊:Neurology [Lippincott Williams & Wilkins] 日期:2026-06-09卷期号:106 (11_Supplement_1)
标识
DOI:10.1212/wnl.0000000000215916
摘要
Objective To systematically review evidence on the therapeutic potential and underlying mechanisms of nanoparticle-based antioxidant formulations in reducing oxidative stress and promoting neuroprotection across neurodegenerative diseases. Background Oxidative stress is a fundamental factor in neuronal injury associated with Alzheimer’s disease, Parkinson’s disease, and related neurodegenerative disorders. Traditional antioxidant therapies have shown limited efficacy due to poor bioavailability, chemical instability, and inadequate passage through the blood–brain barrier. Engineered nanoparticle delivery systems may help overcome these barriers by improving solubility, prolonging drug release, and facilitating targeted deposit within neural tissue. Design/Methods This systematic review follows the PRISMA 2020 framework. Electronic databases including PubMed, Scopus, and ScienceDirect were searched for studies published between January 2010 and June 2025 that evaluated nanoparticle-based antioxidants in preclinical or clinical models of neurodegeneration. Studies were included if they reported quantitative outcomes related to oxidative markers, neuronal survival, or functional recovery. Two independent reviewers screened and extracted data on nanoparticle composition, mechanism of antioxidant action, and efficacy outcomes. Risk-of-bias assessment and data synthesis are ongoing. Results Twenty-five eligible studies were identified. Metal-oxide (cerium oxide, zinc oxide), polymeric, liposomal, and gold-based nanoparticles improved antioxidant stability, reduced reactive oxygen species, and enhanced neuronal viability relative to free antioxidant compounds. Several reports confirmed successful blood–brain-barrier penetration and sustained therapeutic release with minimal toxicity. Methodological heterogeneity currently limits meta-analytic pooling. Conclusions Current evidence supports that nanoparticle-based antioxidant delivery systems enhance bioavailability and demonstrate promising neuroprotective effects across multiple neurodegenerative models. Larger, standardized clinical trials are warranted to establish safety and translational applicability. Disclaimer: Abstracts were not reviewed by Neurology® and do not reflect the views of Neurology® editors or staff . Disclosure: Mr. Memon has nothing to disclose. Ms. Aijaz has nothing to disclose. Dr. Rai has nothing to disclose. Mr. Sahto has nothing to disclose. Mr. Imran has nothing to disclose.